Shelley L McLeod

Dr. Shelley L McLeod

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Chest
Verified
Journal Article
Closed access
SMSamantha MacLean
Samantha MacLean
SMSohail Mulla
Sohail Mulla
EAElie A. Akl
Elie A. Akl
MJMilosz Jankowski
Milosz Jankowski
PVPer Olav Vandvik
Per Olav Vandvik
GGGordon H. Guyatt
Gordon H. Guyatt

1 January 2019 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
RBRomina Brignardello-Petersen
Romina Brignardello-Petersen
MMM. Hassan Murad
M. Hassan Murad
SWStephen D. Walter
Stephen D. Walter
SMShelley L McLeod
Shelley L McLeod
ACAlonso Carrasco-Labra
Alonso Carrasco-Labra
GGGordon H. Guyatt
Gordon H. Guyatt

1 May 2011 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
ASAmit Shah
Amit Shah
GMGregory Mosdossy
Gregory Mosdossy
SMShelley L McLeod
Shelley L McLeod
KLKris Lehnhardt
Kris Lehnhardt
MPMichael Peddle
Michael Peddle
MRMichael Rieder
Michael Rieder

26 February 2019 in Circulation
Verified
Journal Article
Open access
PDF file
DLDouglas S. Lee
Douglas S. Lee
JLJacques S. Lee
Jacques S. Lee
MSMichael J. Schull
Michael J. Schull
BBBjug Borgundvaag
Bjug Borgundvaag
MEMarcia L. Edmonds
Marcia L. Edmonds
JTJack V. Tu
Jack V. Tu
Background: Improved risk stratification of acute heart failure in the emergency department may inform physicians’ decisions regarding patient admission or early discharge disposition. We aimed to validate the previously-derived Emergency Heart failure Mortality Risk Grade for 7-day (EHMRG7) and 30-day (EHMRG30-ST) mortality. Methods: We conducted a multicenter, prospective validation study of patients with acute heart failure at 9 hospitals. We surveyed physicians for their estimates of 7-day mortality risk, obtained for each patient before knowledge of the model predictions, and compared these with EHMRG7 for discrimination and net reclassification improvement. We also prospectively examined discrimination of the EHMRG30-ST model, which incorporates all components of EHMRG7 as well as the presence of ST-depression on the 12-lead ECG. Results: We recruited 1983 patients seeking emergency department care for acute heart failure. Mortality rates at 7 days in the 5 risk groups (very low, low, intermediate, high, and very high risk) were 0%, 0%, 0.6%, 1.9%, and 3.9%, respectively. At 30 days, the corresponding mortality rates were 0%, 1.9%, 3.9%, 5.9%, and 14.3%. Compared with physician-estimated risk of 7-day mortality (PER7; c-statistic, 0.71; 95% CI, 0.64–0.78) there was improved discrimination with EHMRG7 (c-statistic, 0.81; 95% CI, 0.75–0.87; P =0.022 versus PER7) and with EHMRG7 combined with physicians’ estimates (c-statistic, 0.82; 95% CI, 0.76–0.88; P =0.003 versus PER7). Model discrimination increased nonsignificantly by 0.014 (95% CI, −0.009–0.037) when physicians’ estimates combined with EHMRG7 were compared with EHMRG7 alone ( P =0.242). The c-statistic for EHMRG30-ST alone was 0.77 (95% CI, 0.73–0.81) and 30-day model discrimination increased nonsignificantly by addition of physician-estimated risk to 0.78 (95% CI, 0.73–0.82; P =0.187). Net reclassification improvement with EHMRG7 was 0.763 (95% CI, 0.465–1.062) when assessed continuously and 0.820 (0.560–1.080) using risk categories compared with PER7. Conclusions: A clinical model allowing simultaneous prediction of mortality at both 7 and 30 days identified acute heart failure patients with a low risk of events. Compared with physicians’ estimates, our multivariable model was better able to predict 7-day mortality and may guide clinical decisions. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02634762.

28 January 2016 in Blood
Verified
Journal Article
Open access
PDF file
PAPaul E. Alexander
Paul E. Alexander
RBRebecca Barty
Rebecca Barty
YFYutong Fei
Yutong Fei
PVPer Olav Vandvik
Per Olav Vandvik
MPMenaka Pai
Menaka Pai
GGGordon H. Guyatt
Gordon H. Guyatt
The impact of transfusing fresher vs older red blood cells (RBCs) on patient-important outcomes remains controversial. Two recently published large trials have provided new evidence. We summarized results of randomized trials evaluating the impact of the age of transfused RBCs. We searched MEDLINE, EMBASE, CINAHL, the Cochrane Database for Systematic Reviews, and Cochrane CENTRAL for randomized controlled trials enrolling patients who were transfused fresher vs older RBCs and reported outcomes of death, adverse events, and infection. Independently and in duplicate, reviewers determined eligibility, risk of bias, and abstracted data. We conducted random effects meta-analyses and rated certainty (quality or confidence) of evidence using the GRADE approach. Of 12 trials that enrolled 5229 participants, 6 compared fresher RBCs with older RBCs and 6 compared fresher RBCs with current standard practice. There was little or no impact of fresher vs older RBCs on mortality (relative risk [RR], 1.04; 95% confidence interval [CI], 0.94-1.14; P = .45; I2 = 0%, moderate certainty evidence) or on adverse events (RR, 1.02; 95% CI, 0.91-1.14; P = .74; I2 = 0%, low certainty evidence). Fresher RBCs appeared to increase the risk of nosocomial infection (RR, 1.09; 95% CI, 1.00-1.18; P = .04; I2 = 0%, risk difference 4.3%, low certainty evidence). Current evidence provides moderate certainty that use of fresher RBCs does not influence mortality, and low certainty that it does not influence adverse events but could possibly increase infection rates. The existing evidence provides no support for changing practices toward fresher RBC transfusion.

20 August 2015 in Academic Emergency Medicine
Verified
Journal Article
Closed access
PDF file
JYJustin W Yan
Justin W Yan
SMShelley L McLeod
Shelley L McLeod
AIAlla Iansavitchene
Alla Iansavitchene